Alnylam, SOM Biotech, Isis update TTR programs

Data presented at the European Congress on Hereditary ATTR amyloidosis included results from clinical studies of transthyretin amyloid disease therapies from Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY), SOM Biotech S.L. (Barcelona, Spain) and Isis Pharmaceuticals Inc. (NASDAQ:ISIS).

In an 18-month open-label extension

Read the full 405 word article

How to gain access

Continue reading with a
two-week free trial.